|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 340.00 EUR | +1.80% |
|
+0.59% | -4.90% |
| 07-29 | Virbac, without the alibi |  |
| 07-22 | Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VIRBAC | Veterinary Drugs | +1.80% | +0.59% | -4.90% | +3.34% | +3.82% | 3.23B |  |  | |
- Stock Market
- Stocks
- VIRP Stock
- Charts Virbac
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
